## REMARKS

Claims 1 and 22-23 are pending in the above-referenced application. A restriction requirement has been issued where it is required that a species be elected. In response, Applicants have canceled claims 1 and 22-23 without prejudice and new claims 24-37 have been added. However, Applicants do reserve the right to file subsequent continuation and/or divisional applications on subject matter encompassed by the canceled claims. Applicants note that the compounds recited in claim 29 is recites compounds disclosed in Examples 7 and 27.

Applicants assert that the claims are in condition for examination. Early action to that end is respectfully requested. The Examiner is hereby invited to contact Cheryl H. Agris by telephone at (914) 712-0093 if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: Aprill4,2003

Cheryl H. Agris, Reg. No. 34,086

(,/

Counsel for

Novo Nordisk Pharmaceuticals, Inc.

100 College Road West Princeton, NJ 08540

609-919-7779

BEST AVAILABLE COPY